-
Sector Analysis
Human Immunodeficiency Virus (HIV) Epidemiology Analysis and Forecast to 2033
Discovered in 1983, human immunodeficiency virus (HIV) is an RNA virus that reverse transcribes itself into the human host’s DNA and produces lifelong infection. HIV primarily infects cells with CD4+ antigen, such as T-cells and macrophages, two essential white blood cell types (Swinkels et al., 2024) During the acute stage of infection, HIV destroys these CD4+ cells, which allows for the transmission of the virus, opportunistic infections, and the eventual development of AIDS (NIH, 2021; NIH, 2024). Symptoms occur within...
-
Product Insights
Candidiasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Candidiasis - Global Clinical Trials Review, 2024" provides an overview of Candidiasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Candidiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Hepatitis C Therapeutics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hepatitis C Therapeutics . GlobalData epidemiologists estimate that there will be 25.16 million diagnosed prevalent cases of Hepatitis C (HCV) infection in 2024, which is expected to increase slightly to 25.84 million diagnosed prevalent cases by 2029. The HCV treatment landscape has experienced successive waves of revolutionary change and is now dominated by direct-acting antivirals (DAAs). The HCV pipeline holds 68 molecules, with one asset in...
-
Sector Analysis
Hepatitis B Therapeutics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hepatitis B Therapeutics . GlobalData epidemiologists estimate that there will be 21.91 million diagnosed prevalent cases of HBV in 2024, which is expected to increase to 22.43 million diagnosed prevalent cases by 2029. The HBV treatment landscape has experienced successive waves of revolutionary change and is now dominated by antivirals and immunomodulatory therapies. The HBV therapeutics pipeline holds 184 molecules, with one asset in the pre-registration...
-
Sector Analysis
Sepsis Epidemiology Analysis and Forecast to 2033
Sepsis Report Overview In the 8MM, there were 7,614,342 diagnosed incident cases of sepsis in 2023. The diagnosed incident cases of sepsis will register an AGR of more than 2% during 2023-2033. Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection damages its tissues and organs. Sepsis causes multiple organ failure and death, especially if it is not recognized early and treated promptly. Anyone can develop sepsis, but the condition is...
-
Sector Analysis
Gonorrhea (GN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Gonorrhea Marketed and Pipeline Drugs Report Overview Gonorrhea (GN) is an STI caused by the bacterium Neisseria gonorrhoeae. It primarily infects mucous membranes of the reproductive tract but can also infect the throat, eyes, and rectum. The bacteria are typically spread through sexual contact with an infected person, including vaginal, oral, and anal sex. During childbirth, it can also be transferred from mother to child, leading to complications like neonatal conjunctivitis (eye infection), which, if untreated, can cause blindness. Key...
-
Product Insights
HIV Point of Care (POC) Tests Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
HIV Point of Care (POC) Pipeline Market Report Overview HIV Point of care (POC) Tests are rapid tests that are carried out outside of the laboratory setting and are used as a presumptive diagnosis prior to confirmatory laboratory testing. The HIV Point of care (POC) pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are...
-
Sector Analysis
Epstein-Barr Virus Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Epstein-Barr Virus Marketed and Pipeline Drugs Report Overview Epstein-Barr virus (EBV), or human herpes virus 4 is one of the most common viruses in the world. Most people will become infected with EBV during their lifetime and will not have symptoms. It spreads most commonly through bodily fluids, particularly saliva. It can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. EBV is the primary agent of infectious mononucleosis and persists asymptomatically for life in...
-
Product Insights
Human Papillomavirus Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Human Papillomavirus Infections - Global Clinical Trials Review, 2024" provides an overview of Human Papillomavirus Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Human Papillomavirus Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - TAK-007 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-007 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TAK-007 in Primary Mediastinal B-Cell Lymphoma Drug Details:TAK-007 is under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.